Recommendation based on TULIP-SC Phase III trial results showing first-in-class Saphnelo reduced disease activity via once-weekly subcutaneous administration AstraZeneca's Saphnelo (anifrolumab) has ...

The global subcutaneous biologics market is rising due to growing demand for patient-friendly self-administrable therapies and the shift toward biologic drugs with targeted mechanisms of action. The ...

MSD's cancer immunotherapy Keytruda will soon be available as a subcutaneous injection that does away with the need to visit an infusion clinic. Keytruda Qlex (pembrolizumab and berahyaluronidase alfa ...

Knowing where and how to inject GLP-1s can help ensure you are safely and effectively using the medication. Common sites ...

“With today's approval, guselkumab is the first IL-23 inhibitor to offer inflammatory bowel disease patients robust clinical and endoscopic results with a fully subcutaneous induction dose regimen, ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a once-monthly injection of Eli Lilly’s Omvoh for maintenance therapy in adult patients ...

Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...

According to SNS Insider's forecast, the global Antisense and RNAi Therapeutics market will grow from USD 4.15 billion in 2023 to USD 18.48 billion by 2032, at a compound annual growth rate (CAGR) of ...

Learn about innovative treatments for familial chylomicronemia syndrome, including the only FDA-approved drug olizarsen and ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will showcase 46 abstracts, including 12 oral presentations, from its industry-leading hematology portfolio ...